Best Grants for Cancer Nonprofits in American Samoa

Rapid Cancer Grants

Fast Funding for Home Cancer Care Research

We fund healthcare researchers to rapidly explore the feasibility of home infusion as a solution to the ongoing challenges of capacity shortage, site of care management, and financial toxicity in cancer care.

Traditional funding pathways for new care models are too slow to impact patients, so we’ve streamlined the process. By providing funding approvals within 14 days, we enable healthcare teams to quickly launch and evaluate home-based cancer care programs that improve access and affordability.  

What can a Rapid Cancer Grant be used for?

Projects must comprise of research investigating the feasibility, safety, or economic benefit of cancer care at home and must include delivering care to patients via an IRB approved study. IRB approval may be obtained after grant approval. Projects may include assessing suitability of home infusion, enabling access to lab draws at home, or remote care co-ordination to reduce time toxicity for patients.

If you’re a healthcare worker at an oncology practice, hospital or academic institution in the United States and are interested in continuing or launching a new home cancer care initiative, we invite you to apply for a Rapid Cancer Grant.

We are Revolutionaries

Who We Are

We are Revolutionaries -passionate in our singular pursuit of discovering, developing and delivering innovative targeted therapies for patients living with RAS-addicted cancer. At Revolution Medicines, we believe in challenging the status quo to find new therapeutic approaches to some of the toughest cancers. With our first wave of investigational RAS(ON) inhibitors, we are pioneering a new way of targeting the RAS cancer drivers of disease, and we have the potential to change the treatment paradigm in these cancers where there is a significant unmet medical need.

Our mission is to revolutionize treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines.

Research, Grants & Support

At Revolution Medicines, we understand the importance of extending our support of scientific advancement beyond the research we conduct and the medicines we provide.

We support activities that make meaningful information and resources available to the broader medical and scientific communities to help advance science, increase understanding of certain diseases, and enhance patient care.

Charitable Donations

Funding for programs that deliver disease awareness, treatment education, or other healthcare information intended to improve patient understanding and empowerment.

Syndax Pharmaceuticals, Inc.

At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We believe that it takes a community to build a great medicine, and that is why we are working to set the new standard for developing medicines in the field of oncology – one that revolves around collaboration, shared learning, and excellence.

Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.

Educational Funding

At Syndax, we are committed to the goal of supporting objective, balanced and scientifically rigorous education that furthers improvements in science, medicine, and patient care. We accomplish this goal, in part, by providing grants for independent medical education (IME) programs. These can include live, online, and/or enduring programs that educate healthcare providers (HCPs), patients, or caregivers. Programs that are funded via Syndax medical education grants must be primarily dedicated, in both effort and time, to medical, health or scientific topics that are objective, balanced, unbiased, and scientifically rigorous. Medical education grants must never be made with the intent to directly or indirectly reward, influence or encourage the recipient to prescribe, purchase, sell or arrange for any Syndax product.

The Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN) Grant, offered by the Patient Advocate Foundation, provides crucial financial assistance to patients facing this cancer type. It covers out-of-pocket healthcare costs, including medication copays and insurance premiums, ensuring those affected can access necessary treatments. With a focus on personalized case management, the foundation has supported millions in navigating their healthcare needs, emphasizing the importance of timely and affordable care for patients diagnosed with MPN.

The AACR June L. Biedler Prize for Cancer Journalism

Prize Summary

The AACR June L. Biedler Prize for Cancer Journalism was established by the AACR in 2015 to raise awareness of the critical role that the media play in educating the public about cancer and cancer research.

Funded by a major bequest to the AACR from cancer research pioneer Dr. June L. Biedler, a scientist, mentor, and former member of the AACR Board of Directors, this prize showcases outstanding examples of cancer journalism and recognizes individual professional journalists who have produced accurate, informative, and compelling stories that enhance the public’s understanding of cancer, cancer research, cancer advocacy, or cancer policy.

The prize provides an unrestricted cash award of $5,000 and a commemorative award.

Categories

Each submission may be considered for only one category, as selected by the candidate on the application form.

Applicants may submit in any of the following categories:

Prize Acceptance

Awardees will be able to accept the prize during the AACR Annual Meeting 2027 in Orlando, April 2-7, 2027.

Gray for Glioblastoma Society

A 501 (c) 3 created to raise awareness for and funds to support Glioblastoma Multiforme research by accepting donations and donating to cancer care and research facilities. Our organization has gifted over $275,000 to support GBM research projects at renowned cancer centers including The Ty Miller Lab at Case Western Reserve University, Dana Farber Cancer Institute, Children’s Hospital LA/Saban Research Institute and The Preston Robert Tisch Brain Tumor Center at Duke. We accomplish this while simultaneously creating a hopeful and positive space and providing resources and a space of community through our social media and events.

Gray for Glioblastoma Grant

Gray for Glioblastoma Society (GFG) is dedicated to funding projects that advance glioblastoma (GBM) research and move the needle forward in care and quality of life. We invite proposals that align with our mission and demonstrate meaningful impact in the GBM space.

St. Baldrick's Foundation

The St. Baldrick's Foundation is a volunteer and donor powered charity committed to supporting the most promising research to find cures for childhood cancers and give survivors long and healthy lives. It started with a friendly dare: would you shave your head to raise money for kids’ cancer research? What happened next would change the world. This bold act of baldness has gained major momentum, since its start in 2000. Today, we have more than 1,000 head-shaving events taking place around the world at pubs, restaurants, schools, churches, parks, firehouses, military bases – you name it. It is our constituents’ way of changing the world, in a meaningful way. Volunteers also raise funds through athletic challenges, livestream fundraisers and many other activities.

Since the Foundation's first grants as an independent charity in 2005, St. Baldrick's has invested more than $380 million in childhood cancer research grants worldwide.

About Allied World

Allied World Assurance Company Holdings, Ltd, through its subsidiaries, is a global provider of insurance and reinsurance solutions. The company operates under the brand Allied World and has supported clients, cedents and trading partners with thoughtful service and meaningful coverages since 2001. Since the inception of St. Baldrick’s, Allied World has supported childhood cancer research through the Foundation, and it is the largest of many reinsurance company sponsors, making this life-saving mission a top priority.

Survivorship and Supportive Care Research Grant

These grants are for specific one-year research projects which are hypothesis-driven and focus on areas related to survivorship and supportive care of children and adolescents with cancer. Examples include but are not limited to: studies related to the burden of morbidity, cause-specific mortality, understanding the pathogenesis of treatment-related complications, patient-reported outcomes or quality of life, health communication, health promotion, and psychosocial support across the trajectory from diagnosis to survivorship or end-of-life care.

Projects must have direct applicability and relevance to pediatric cancer. They may be in any discipline of basic, clinical, translational, or epidemiological research.

About the Emporia Community Foundation

Our Mission

To connect caring people with causes that build stronger communities within the Emporia area which includes Chase, Coffey, Greenwood, Lyon, Morris, Osage and Wabaunsee counties.

Choose How You Respond Fund (in memory of Dr. Bryan Douglas) 

The purpose of the Choose How You Respond Fund is to provide funds to qualified individuals to cover expenses related to the treatment of cancer.

About the Emporia Community Foundation

Our Mission

To connect caring people with causes that build stronger communities within the Emporia area which includes Chase, Coffey, Greenwood, Lyon, Morris, Osage and Wabaunsee counties.

Never Let Go Fund

The purpose of the Never Let Go Fund is to provide funds to qualified individuals to cover expenses related to the treatment of childhood cancer. Grant requests will be considered for children under the age of 18.

About Pfizer Grants

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Interventional Research Studies of Brentuximab Vedotin-Based Novel Combinations in AITL and PTCL-NOS

This competitive program is designed to support interventional InvestigatorSponsored Research aimed at generatin clinical evidence for brentuximab vedotin in novel combination approaches in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma–not otherwise specified (PTCL-NOS).

Project Types and Area of Interest

Studies considered for Pfizer support should address key clinical and scientific gaps in the use of brentuximab vedotin in AITL and PTCL-NOS irrrespective of CD30 expression, with a focus on evaluating the safety and efficacy of novel brentuximab vedotin–based combinations with therapies available for PTCL treatment that are supported by a clear scientific rationale grounded in mechanism of action and/or disease biology.

About Us

Children’s Cancer Research Fund is a national nonprofit dedicated to ending childhood cancer. Our main focus is to support the research of bright scientists across the country whose ideas can make the greatest impact for children fighting cancer. We also fund resources and programs that help kids and families as they navigate the difficult experience of cancer treatment and survivorship.

Since 1981, we’ve contributed over $235 million to research, support programs for children and families, and awareness and education outreach. In 2024, over 81 percent of funds raised went directly to these program services areas.

Children’s Cancer Research Fund (CCRF) is a national nonprofit committed to finding safer, more effective therapies for kids battling cancer. Thanks to donors and partners around the country, we have contributed over $235 million to research, education and awareness, and quality-of-life programs for childhood cancer families. We believe kids deserve safer, less toxic treatments, and we’re committed to funding groundbreaking research and services that enhance healing and care.

In 2026, Children’s Cancer Research Fund will focus our research funding efforts on three main areas:

• Hard-to-Treat Cancers
• Survivorship
• Health Disparities

Accelerating Hope: Clinical Trials for Hard-to-Treat Cancers Award

This funding opportunity is limited to support for clinical trials focused on hard-to-treat cancers, prioritizing Phase 0 – Phase 2 studies. Learn more about eligibility criteria and other key details below.

The Healthy After Cancer Award, offered by the Children's Cancer Research Fund, focuses on enhancing the quality of life for childhood cancer survivors. This funding supports research aimed at addressing the long-term effects of cancer therapy, prioritizing survivorship interventions over new treatment development. With a commitment to improving health outcomes for young survivors, this award underscores the importance of addressing unique challenges faced by this population.

The Eliminating Disparities in Childhood Cancers Award, offered by the Children’s Cancer Research Fund, supports innovative research aimed at reducing health disparities in childhood cancer. This initiative prioritizes proposals that identify modifiable risk factors and mechanisms of disparities, emphasizing the importance of improving access to care and treatment outcomes. With over $235 million invested since 1981, CCRF is dedicated to enhancing the quality of life for children and families affected by cancer.

The Accelerating Impact for Hard-to-Treat Cancers Award, offered by the Children's Cancer Research Fund, focuses on pre-clinical research to enhance treatment outcomes for pediatric cancers that are difficult to treat. The award supports innovative studies, including pilot projects and the development of new technologies. As a nonprofit, CCRF has invested over $235 million in initiatives since 1981, aiming to improve therapies and support for children battling cancer, thereby fostering safer and more effective treatment options.

Pershing Square Lotus Award for Ovarian Cancer Research

The Pershing Square Foundation (PSF) has worked across sectors to catalyze innovative approaches to the most difficult problems. Talented individuals have always been at the center of our approach. We aim to support leaders who transform systems, embrace new paradigms, and have an innate drive to make an impact.

PSF has funded pioneering cancer researchers through the Pershing Square Sohn Cancer Research Alliance for over a decade and supported women’s health initiatives in New York City. Through this Request for Proposals (RFP), PSF aims to combine these two priority areas of women’s health and cancer to shine a light on one of the most understudied and underfunded cancers—ovarian cancer. Ovarian cancer is the deadliest gynecologic cancer, with 80% of women diagnosed at an advanced stage. Only 27% of women diagnosed during an advanced stage survive for five years. Ovarian cancer remains a disease with a poor prognosis due to limited early detection and treatment options.

PSF supports research efforts by 

• deploying capital quickly, 
• funding high-risk, high-reward ideas, 
• bringing new perspectives into a field, 
• encouraging collaboration, and 
• leveraging our vast network. We challenge our scientific partners to think creatively and across silos, to spur innovation to fight ovarian cancer.

Through the Pershing Square Lotus Award for Ovarian Cancer Research, PSF is looking for investigators who are either already working on a promising project in ovarian cancer or in another type of cancer that could have an impact on ovarian cancer. Grantees each receive $250,000 a year for three years, totaling $750,000.

Researchers who are not studying ovarian cancer are encouraged to apply and required to find a collaborator with experience in ovarian cancer research.

This award aims to 

• inspire investigators with unique expertise to apply their knowledge to ovarian cancer and 
• empower ovarian cancer researchers to pursue their boldest, most innovative ideas. Facing a disease where too few have survived to-date, PSF ultimately aims to create a culture around ovarian cancer that offers women hope, akin to the breast cancer community. PSF is passionate about changing outcomes for tens of thousands of women a year and is hopeful that future scientific discoveries will allow for more survivors who can share their stories for years to come.

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Patient Travel Grant Program

A mesothelioma diagnosis and treatment often require the patient and their family to incur numerous expenses as part of their treatment. Travel to treatment, alone, can cause a significant financial burden on the patient, which might even cause the patient to not seek treatment away from home, even it’s their best option. To ensure that all patients have the ability to seek specialized help and treatments, the Mesothelioma Applied Research Foundation administers its Travel Grant Program.

The Meso Foundation’s Patient Travel Grant Program, founded by Mary and Bob Cosentino, provides travel grants to patients and one caregiver traveling for an initial consult and/or for clinical trial treatments.

• The type of eligible travel must fall into at least one of these two categories:
  • One trip for one initial consultation with a mesothelioma specialist.
  • Multiple trips to participate in an interventional clinical trial (found on clinicaltrials.gov).

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Bret A. Rosenthal Patient Assistance Fund

Patients diagnosed with cancer at a younger age often face greater financial burdens. This is a time in a patient’s life when they are raising a family, starting a career, or have not accumulated savings. For patients 49 and under, the Foundation administers the Bret A. Rosenthal Patient Assistance Fund grant program. This program is made possible by the generosity of the Rosenthal family.

Grants Program for Penn Investigators - Early career awards for Fellows, Postdocs and Instructors

Research grant applications in basic science, prevention, disease interception, and early detection that are relevant to the study of BRCA1/2 will be considered. The Basser Cancer Interception Institute focuses on funding new endeavors in emerging, orthogonal fields beyond DNA damage (e.g. mechanisms of haploinsufficiency, cancer evolution and tissue tropism). 

Grants focused on the following are of particular interest:

• Cancer interception and the pre-cancer disease state
• Issues relevant to men (including but not limited to prostate cancer, pancreatic cancer, male breast cancer)
• Potential for translation into clinical practice
• Early detection

Grants that demonstrate a potential for translation into clinical practice will be prioritized for funding.

Early career awards for Fellows, Postdocs and Instructors

Early career awards for Fellows, Postdocs and Instructors up to $100,000 for one year. Grants are eligible for competitive renewal upon reapplication and are contingent on progress the first year.

The CORE Funding: AHNS Presidential Award supports innovative research that integrates emerging technologies in head and neck cancer studies. This initiative aims to address critical gaps in early detection and treatment, especially for patients with advanced disease. By leveraging tools such as AI and advanced imaging, the program seeks to enhance understanding of disease mechanisms and improve patient-centered intervention strategies, ultimately advancing the field of otolaryngology.

The CORE Funding: AHNS Thyroid Cancer Survivors’ Association Award aims to support vital research projects focused on thyroid cancer, encompassing prevention, diagnosis, treatment, and outcomes. This initiative by the American Academy of Otolaryngology - Head and Neck Surgery Foundation promotes advancements in the field through funding opportunities that enhance research capabilities and foster collaboration among researchers. Through the support of this award, significant strides can be made in understanding and combating thyroid cancer.

The CORE Funding: AHNS Trainee Pilot Research Award supports innovative research in head and neck oncology, encouraging trainees to engage in clinical or translational studies. Since its inception, CORE has provided over $14 million in grants, facilitating significant advancements in otolaryngology. This initiative aims to enhance research efforts, reduce fragmentation, and promote collaboration among various stakeholders to improve outcomes for patients with head and neck neoplastic diseases.

The CORE Funding: Lilly Research Grant aims to advance research on genetic hearing loss. It invites investigators to explore the genetic factors contributing to hearing loss, promoting innovative projects that enhance understanding in this critical area. Supported by the American Academy of Otolaryngology - Head & Neck Surgery Foundation, the grant fosters significant research efforts to improve outcomes and strategies in otolaryngology, ensuring a comprehensive approach to hearing health.

About Pfizer External Research & Grants

Pfizer External Research & Grants (ER&G) supports independent research, education, and QI initiatives to improve patient outcomes in areas of unmet need. Competitive grants are awarded through transparent RFPs reviewed by independent expert panels.

About ASCP

American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organization for pathologists and laboratory professionals, with more than 100,000 members. ASCP provides excellence in education, certification, and advocacy on behalf of patients and the laboratory workforce. With a portfolio of more than 900 educational activities, ASCP is the worldwide leader in providing CME/CMLE credit for the entire laboratory team.

Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)

The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer Inc. and with participation from the American Society of Clinical Oncology (ASCO, invites proposals for pathology-centric Quality Improvement (QI) initiatives aimed at optimizing molecular testing pathways in the management of metastatic colorectal cancer (mCRC). This grant opportunity seeks to fund sustainable projects that improve biomarker testing practices, strengthen targeted therapy selection, and support care teams in implementing patient-centered protocols. 

The overarching goal of this program is to advance diagnostic excellence and improve treatment decision-making for patients with mCRC.

The American Academy of Otolaryngology–Head and Neck Surgery Foundation is inviting proposals for the CORE Funding: AHNS Presidential Award, aimed at enhancing value-based care in head and neck oncology. This initiative focuses on improving quality, efficiency, and patient outcomes through data-driven strategies. Key proposal components include quality and process measures, along with identifying care gaps. Priority areas include behavioral health integration and innovative contracting models, promoting scalable solutions that enhance care quality and value in this specialty.

National Collegiate Cancer Foundation

The National Collegiate Cancer Foundation (NCCF) is a national 501(c)(3) nonprofit organization dedicated to supporting young adults diagnosed with or impacted by cancer. Its mission is to provide services, resources, and need-based financial assistance that empower survivors and their families to adopt a resilient “Will Win” mindset throughout treatment and beyond. NCCF is one of the few national organizations that provides direct financial support to young adult cancer survivors, primarily through its Survivor and Legacy Scholarships, which assist students pursuing higher education during or after treatment. The Foundation also promotes cancer awareness and prevention within the young adult community. Recognizing that adolescents and young adults (ages 15–39) face unique challenges—including delayed diagnoses, limited access to insurance and clinical trials, fertility concerns, employment disruption, and social isolation—NCCF prioritizes addressing the significant service gaps affecting this underserved population. Operated entirely by volunteers, NCCF remains committed to advancing educational access, financial relief, and hope for young adult cancer survivors nationwide.

NCCF: Legacy Scholarship Program

The National Collegiate Cancer Foundation (NCCF) offers $1,000 competitive scholarships to young adults pursuing higher education who have lost a parent or guardian to cancer. The award is designed to provide financial assistance and encouragement to students continuing their education despite personal loss. Applications are evaluated based on the applicant’s personal journey, sources of encouragement, demonstrated financial need, notable accomplishments, and the quality of recommendations. The scholarship recognizes resilience, perseverance, and academic commitment in the face of cancer-related loss.

Funding Innovative Research

Cannonball Kids’ cancer Foundation (CKc) prioritizes funding clinical trials, research that is nearing translation to a clinical trial, and young investigator grants.

Grants funded by CKc must be innovative and provide better quality of life or symptom relief than current treatments. 

When possible, CKc will prioritize funding research:

• with a focus on cancers that are under-funded or under-researched,
• with a focus on patient populations who are traditionally underserved.

When possible, CKc will prioritize funding researchers of diverse backgrounds.

For CKc, “innovation” means the invention or application of novel methods or treatments, specifically treatments that have fewer side-effects than standard care, increase a child’s quality of life, and/or create an option for care where there otherwise were few or none (either on primary diagnosis, relapse, or for recalcitrant cancers).

Research Grants

Grant Program: Clinical Trial

$200,000 over 3 years

• PI must hold an academic appointment at the Assistant Professor level or higher
• Preclinical studies must be complete
• If an FDA Investigational New Drug (IND) application is necessary for the proposed clinical study, the IND application should already have passed FDA initial review and be active
• If the PI has recruited additional patient enrollment sites, local IRB approval must be obtained for each site.

• How many treatment options would this study provide for children?
• How accessible is this study for children and families to access?

Funding Innovative Research

Cannonball Kids’ cancer Foundation (CKc) prioritizes funding clinical trials, research that is nearing translation to a clinical trial, and young investigator grants.

Grants funded by CKc must be innovative and provide better quality of life or symptom relief than current treatments. 

When possible, CKc will prioritize funding research:

• with a focus on cancers that are under-funded or under-researched,
• with a focus on patient populations who are traditionally underserved.

When possible, CKc will prioritize funding researchers of diverse backgrounds.

For CKc, “innovation” means the invention or application of novel methods or treatments, specifically treatments that have fewer side-effects than standard care, increase a child’s quality of life, and/or create an option for care where there otherwise were few or none (either on primary diagnosis, relapse, or for recalcitrant cancers).

Research Grants

Grant Program: Young Investigator

$100,000 over 3 years

• PI must hold an academic appointment at the instructor level or higher
• PI must be within 5 years of completing a training fellowship in Pediatric Hematology/Oncology or a closely related discipline that has direct clinical contact with pediatric cancer patients
• Research must be within 2-3 years to translation to a clinical trial or already associated with a clinical trial

• Evidence of Mentor's commitment to the PI's career development plan
• Translational potential